Skip to main content

Liver Cancer Clinical Trials

Review the liver cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 162

Y-90 SIRT and SBRT for the Treatment of Unresectable Liver Cancer
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Ipilimumab and Nivolumab with Stereotactic Body Radiotherapy Followed by Surgical Resection for the Treatment of Locally Advanced Borderline Resectable Hepatocellular Cancer
Status: Active
Location: University of Hawaii Cancer Center, Honolulu, Hawaii
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Cryoablation and Hepatic Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab for the Treatment of Locally Advanced or Metastatic and/or Unresectable Liver cancer
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination with Gemcitabine, Cisplatin and Durvalumab for the Treatment of Biliary Tract Cancer Patients with Peritoneal Metastases
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Yttrium-90 Radioembolization in Combination with Tremelimumab and Durvalumab for Treating Patients with Locally Advanced, Unresectable or Oligo-metastatic Intrahepatic Cholangiocarcinoma Who are Not Candidates for Curative Therapy, RAIDEN Trial
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Emavusertib in Combination with Cisplatin, Gemcitabine, and Durvalumab for the Treatment of Advanced Unresectable or Metastatic Biliary Tract Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Status: Active
Location: 2 locations
Tumor Treating Fields Therapy (NovoTTF™-200M and NovoTTF-200A Systems) for the Treatment of Refractory Spinal Metastasis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tumor Treating Fields Therapy in Combination with Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Status: Active
Location: 2 locations
Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Pomalidomide and Nivolumab for the Treatment of Virus-Associated Malignancies with or without HIV
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Status: Active
Location: See ClinicalTrials.gov
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
Status: Active
Location: See ClinicalTrials.gov
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Status: Active
Location: See ClinicalTrials.gov
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Status: Active
Location: See ClinicalTrials.gov
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: Active
Location: See ClinicalTrials.gov
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)
Status: Active
Location: See ClinicalTrials.gov